FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2182860128> ?p ?o ?g. }

• W2182860128 endingPage "28" @default.
• W2182860128 startingPage "22" @default.
• W2182860128 abstract "Our understanding of metastatic disease has evolved significantly in the last 20 years. Considered strictly a systemic issue, local treatment would only have significant impact in terms of palliation. However, Hellman and Weichselbaum stated that there might be an intermediate state, in which controlling limited metastatic sites could improve oncologic outcomes. This is called an oligometastatic state, a point between locally confined cancer and widespread disease [ 1 Hellman S. Weichselbaum R.R. Oligometastases. J. Clin. Oncol. 1995; 13: 8-10 Crossref PubMed Google Scholar , 2 Weichselbaum R.R. Hellman S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 2011; 8: 378-382 Crossref PubMed Scopus (622) Google Scholar ]. As treatment with chemotherapy alone for non small cell lung cancer (NSCLC) yields median survivals of 8–11 months [ [3] Grossi F. Kubota K. Cappuzzo F. et al. Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. Oncologist. 2010; 15: 1102-1112 Crossref PubMed Scopus (56) Google Scholar ] and minimal chances of long term survival, new strategies are needed to offer better odds for metastatic patients. Outcomes tend to be better in patients with low volume metastatic disease. [ 4 Mok T.S. et al. Personalized medicine in lung cancer: what we need to know. Nat. Rev. Clin. Oncol. 2011; 8: 661-668 Crossref PubMed Scopus (121) Google Scholar , 5 Niibe Y. Chang J.Y. et al. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm. Med. 2012; ([Epub 2012 August 22]): 261096 PubMed Google Scholar ], leading us to question whether the oligometastatic group of patients will gain from a more radical treatment paradigm. In this setting, ablative treatments like surgery or SBRT may provide longer survival and better local control times. There is a rationale for the use of ablative local treatments, as most failures after chemotherapy occur at sites initially affected by disease, and these sites could be a source of further dissemination. Also, chemotherapy resistance can adversely impact resolution of metastatic disease [ [6] Westover K. Timmerman R. et al. SABR for aggressive local therapy of metastatic cancer: a new paradigm for metastatic non-small cell lung cancer. Lung Cancer. 2015; 89: 87-93 Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar ]. In rare cases, the abscopal effect (an immune effect arising after radiotherapy in non irradiated metastatic sites) has been described [ 7 Postow M.A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Eng. J. Med. 2012; 366: 925-931 Crossref PubMed Scopus (1493) Google Scholar , 8 Kaminski J.M. et al. The controversial abscopal effect. Cancer Treat. Rev. 2005; 31: 159-172 Abstract Full Text Full Text PDF PubMed Scopus (174) Google Scholar ]. In this review article, we address the impact of SBRT in oligometastatic NSCLC, the most relevant prognostic factors, indications and a site specific review. This review will focus on SBRT for extracranial disease as the role for intracranial SBRT is established." @default.
• W2182860128 created "2016-06-24" @default.
• W2182860128 creator A5016241442 @default.
• W2182860128 creator A5054828984 @default.
• W2182860128 date "2016-02-01" @default.
• W2182860128 modified "2023-10-11" @default.
• W2182860128 title "The role of stereotactic ablative radiotherapy (SBRT) in the management of oligometastatic non small cell lung cancer" @default.
• W2182860128 cites W111691901 @default.
• W2182860128 cites W1501842160 @default.
• W2182860128 cites W1528207664 @default.
• W2182860128 cites W1607653498 @default.
• W2182860128 cites W1636066714 @default.
• W2182860128 cites W1670552811 @default.
• W2182860128 cites W1891507428 @default.
• W2182860128 cites W1969531640 @default.
• W2182860128 cites W1972637885 @default.
• W2182860128 cites W1975340808 @default.
• W2182860128 cites W1977465552 @default.
• W2182860128 cites W1979088060 @default.
• W2182860128 cites W1987288037 @default.
• W2182860128 cites W1990815091 @default.
• W2182860128 cites W2009087529 @default.
• W2182860128 cites W2011419722 @default.
• W2182860128 cites W2013333204 @default.
• W2182860128 cites W2022980644 @default.
• W2182860128 cites W2024501410 @default.
• W2182860128 cites W2025886796 @default.
• W2182860128 cites W2029982246 @default.
• W2182860128 cites W2030505692 @default.
• W2182860128 cites W2036504258 @default.
• W2182860128 cites W2037407820 @default.
• W2182860128 cites W2046609575 @default.
• W2182860128 cites W2047930883 @default.
• W2182860128 cites W2052354574 @default.
• W2182860128 cites W2058188403 @default.
• W2182860128 cites W2064717658 @default.
• W2182860128 cites W2065834230 @default.
• W2182860128 cites W2066254965 @default.
• W2182860128 cites W2068469705 @default.
• W2182860128 cites W2069445013 @default.
• W2182860128 cites W2070161887 @default.
• W2182860128 cites W2076350704 @default.
• W2182860128 cites W2077795406 @default.
• W2182860128 cites W2083624286 @default.
• W2182860128 cites W2084089297 @default.
• W2182860128 cites W2084584970 @default.
• W2182860128 cites W2091387599 @default.
• W2182860128 cites W2091755109 @default.
• W2182860128 cites W2092088418 @default.
• W2182860128 cites W2093921289 @default.
• W2182860128 cites W2100625706 @default.
• W2182860128 cites W2103874167 @default.
• W2182860128 cites W2108789863 @default.
• W2182860128 cites W2111247556 @default.
• W2182860128 cites W2112579119 @default.
• W2182860128 cites W2114932214 @default.
• W2182860128 cites W2115329455 @default.
• W2182860128 cites W2115797000 @default.
• W2182860128 cites W2122798232 @default.
• W2182860128 cites W2126908156 @default.
• W2182860128 cites W2127136307 @default.
• W2182860128 cites W2130693156 @default.
• W2182860128 cites W2131303800 @default.
• W2182860128 cites W2133422369 @default.
• W2182860128 cites W2136023414 @default.
• W2182860128 cites W2137602317 @default.
• W2182860128 cites W2142138307 @default.
• W2182860128 cites W2143853878 @default.
• W2182860128 cites W2144518271 @default.
• W2182860128 cites W2153929368 @default.
• W2182860128 cites W2164621703 @default.
• W2182860128 cites W2166459387 @default.
• W2182860128 cites W2168325971 @default.
• W2182860128 cites W2169895148 @default.
• W2182860128 cites W2170133743 @default.
• W2182860128 cites W2238818897 @default.
• W2182860128 cites W4231096603 @default.
• W2182860128 cites W4239112513 @default.
• W2182860128 cites W4240340450 @default.
• W2182860128 doi "https://doi.org/10.1016/j.lungcan.2015.11.015" @default.
• W2182860128 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26775592" @default.
• W2182860128 hasPublicationYear "2016" @default.
• W2182860128 type Work @default.
• W2182860128 sameAs 2182860128 @default.
• W2182860128 citedByCount "18" @default.
• W2182860128 countsByYear W21828601282016 @default.
• W2182860128 countsByYear W21828601282017 @default.
• W2182860128 countsByYear W21828601282018 @default.
• W2182860128 countsByYear W21828601282019 @default.
• W2182860128 countsByYear W21828601282020 @default.
• W2182860128 countsByYear W21828601282021 @default.
• W2182860128 countsByYear W21828601282022 @default.
• W2182860128 countsByYear W21828601282023 @default.
• W2182860128 crossrefType "journal-article" @default.
• W2182860128 hasAuthorship W2182860128A5016241442 @default.
• W2182860128 hasAuthorship W2182860128A5054828984 @default.
• W2182860128 hasConcept C121608353 @default.
• W2182860128 hasConcept C126322002 @default.

• next